Benefits Of Bifidobacterium Breve M-16v Supplementation In Preterm Neonates - A Retrospective Cohort Study

BackgroundSystematic reviews of randomised controlled trials report that probiotics reduce the risk of necrotising enterocolitis (NEC) in preterm neonates.AimTo determine whether routine probiotic supplementation (RPS) to preterm neonates would reduce the incidence of NEC.MethodsThe incidence of NEC >= Stage II and all-cause mortality was compared for an equal period of 24 months 'before' (Epoch 1) and 'after' (Epoch 2) RPS with Bifidobacterium breve M-16V in neonates <34 weeks. Multivariate logistic regression analysis was conducted to adjust for relevant confounders.ResultsA total of 1755 neonates (Epoch I vs. II: 835 vs. 920) with comparable gestation and birth weights were admitted. There was a significant reduction in NEC >= Stage II: 3% vs. 1%, adjusted odds ratio (aOR) = 0.43 (95% CI: 0.21-0.87); 'NEC >= Stage II or all-cause mortality': 9% vs. 5%, aOR = 0.53 (95% CI: 0.32-0.88); but not all-cause mortality alone: 7% vs. 4%, aOR = 0.58 (95% CI: 0.31-1.06) in Epoch II. The benefits in neonates <28 weeks did not reach statistical significance: NEC >= Stage II: 6% vs. 3%, aOR 0.51 (95% CI: 0.20-1.27), 'NEC >= Stage II or all-cause mortality', 21% vs. 14%, aOR = 0.59 (95% CI: 0.29-1.18); all-cause mortality: 17% vs. 11%, aOR = 0.63 (95% CI: 0.28-1.41). There was no probiotic sepsis.ConclusionRPS with Bifidobacterium breve M-16V was associated with decreased NEC >= Stage II and 'NEC >= Stage II or all- cause mortality' in neonates <34 weeks. Large sample size is required to assess the potential benefits of RPS in neonates <28 weeks.